A Phase 3 interventional study of Benralizumab and Mepolizumab in Eosinophilic Granulomatous Vasculitis, sponsored by AstraZeneca. Active, not recruiting at 50 sites in 9 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Churg-Strauss Syndrome with a site in United States — 8 open to participants now, 12 under way, 4 of them phase 3. Churg-Strauss Syndrome · United States.
Among the 26 studies in Churg-Strauss Syndrome with a site in United States, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2019, is one of 6 in phase 3, reaches primary completion later than 0 of the 11 other live ones, and was the 21st registered.
61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.
Browse Churg-Strauss Syndrome studies →8 of the 26 studies in Churg-Strauss Syndrome with a site in United States are open now. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
AstraZeneca · Sites in United States, Brazil, Canada and 7 more countries
Ages 6–17
Peter Merkel · Sites in United States, Canada
Ages 5+
University of Pennsylvania · Sites in United States, Canada
University of Pennsylvania · Sites in United States
Ages 18–50 · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Churg-Strauss Syndrome studies recruiting now, 11 (79%) set no upper age limit and 3 (21%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 6
First in 2000; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 66 across 30 interventional studies indexed under Churg-Strauss Syndrome.
Median enrollment 60 across the 13 interventional studies, 467 across the 13 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 26 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 4 studies filed under Churg-Strauss Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies in Churg-Strauss Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06046222NS Pharma, Inc.Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Churg-Strauss Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, double blind, active-controlled, parallel group, multicenter 52-week Phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous (SC) injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy.
All patients who complete the 52-week double-blind treatment period on IP may be eligible to continue into an open label extension (OLE) period. The OLE period is intended to allow each patient at least 1 year of treatment with open-label benralizumab 30 mg administered SC (earlier enrolled patients may therefore be in the OLE for longer than 1 year).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
History of relapsing (at least 1 confirmed EGPA relapse within last 2 years and > 12 weeks prior to screening), or (failure to attain remission, defined as BVAS=0 and oral (OCS) dose \<=7.5 mg/day of prednisolone or equivalent, following standard induction regimen for at least 3 months and within 6 months prior to screening, or recurrence of symptoms upon OCS tapering at any dose of ≥7.5 mg/day prednisolone or equivalent.
If induction with glucocorticoidsalone, patient must have failed to attain remission after 3 months and the glucocorticoid dose must be ≥15 mg/day prednisolone or equivalent for the 4 weeks prior to randomization.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1x benralizumab SC injection + 3x placebo to mepolizumab SC injections
Biological: Benralizumab · Biological: Placebo to Mepolizumab
3x mepolizumab SC injections + 1x placebo to benralizumab SC injection
Biological: Mepolizumab · Biological: Placebo to Benralizumab
30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)
3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)
Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)
Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)
Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48
Percentage of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 4 mg/day (main remission definition) at both Weeks 36 and 48.
Time frame: Week 36 and Week 48
Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48
Supportive endpoint: Proportion of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 7.5 mg/day (supportive remission definition) at both Weeks 36 and 48.
Time frame: Week 36 and Week 48
Total Accrued Duration of Remission During DB Treatment Period
Total accrued duration of remission for the following categories: 0 week, \> 0 to \< 12 week, 12 to \< 24 week, 24 to \< 36 week, ≥ 36 week.
Time frame: from baseline to end of DB period, 52 Weeks.
Total Accrued Duration of Sustained Remission During DB Treatment Period
Total accrued duration of sustained remission for the following categories: 0 week, \> 0 to \< 12 week, 12 to \< 24 week, 24 to \< 36 week, ≥ 36 week.
Time frame: from baseline to end of DB period, 52 Weeks
Time From Randomization to First Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse
Time from randomization to first Eosinophilic Granulomatosis with Polyangiitis (EGPA) relapse, where relapse is defined as any of the following: * Active vasculitis (BVAS \> 0); OR * Active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR * Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions; warranting any of the following: * An increased dose of OCS therapy to \> 4 mg/day prednisolone total daily dose; OR * An increased dose or addition of immunosuppressive therapy; OR * Hospitalization related to EGPA worsening Calculated using the Kaplan-Meier technique.
Time frame: from baseline to end of DB period, 52 Weeks
Annualized Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse Rate
Annualized Eosinophilic Granulomatosis with Polyangiitis (EGPA) relapse rate through end of DB treatment period. The estimate of annualized relapse rate (relapses per year) and the corresponding 95% CIs were calculated using a negative binomial model. The response variable in the model is the number of relapses experienced by a subject up to Week 52. The logarithm of the subject's corresponding follow-up time up to Week 52 was used as an offset variable to adjust for subjects having different follow-up times during which the events occur. The covariates in the model include treatment arm, baseline dose of prednisone, baseline BVAS and region.
Time frame: from baseline to end of DB period, 52 Weeks
Average Daily Dose of Prednisolone/Prednisone and Change From Baseline During Week 48 Through 52
Average daily dose of prednisolone/prednisone and change from baseline during Week 48 through 52, or last 28 days prior to last double-blind assessment for those that withdrew
Time frame: last 4 weeks of DB period
Proportion of Patients With Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52
Proportion of patients with average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: 0 mg; \>0 to ≤ 4 mg; \> 4 to ≤ 7.5 mg and \> 7.5 mg
Time frame: last 4 weeks of DB period
Percentage Reduction From Baseline in Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52
Percentage reduction from baseline in average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: no reduction or withdrawal from treatment; \< 25% reduction; 25 to \< 50% reduction; 50 to \<75% reduction; 75 to \< 100% reduction; 100% reduction.
Time frame: last 4 weeks of DB period
Proportion of Subjects With Reduction From Baseline in Average Daily Dose of Prednisolone/Prednisone During Week 48 Through 52
Proportion of subjects with reduction from baseline in average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: \>= 50% reduction; 100% reduction; OCS dose \<= 4 mg/day.
Time frame: last 4 weeks of DB period
Proportion of Subjects Who Achieve Clinical Benefit
Proportion of subjects who achieved any clinical benefit definition 1 (defined as any of the following: * Main remission at any time in DB period * \>= 50% reduction in OCS dose in Weeks 48 to 52 * EGPA relapse free in DB period) and subjects who achieved complete response definition 1 (defined as meeting all the definition 1 criteria above.)
Time frame: from baseline to end of DB period, 52 Weeks
Proportion of Patients Who Have Achieved Remission Within the First 24 Weeks and Remained in Remission for Remainder of the Double-blind Treatment Period
Proportion of patients who have achieved remission within the first 24 weeks and remained in remission for remainder of the double-blind treatment period
Time frame: from baseline to end of DB period, 52 Weeks
Change From Baseline in Birmingham Vasculitis Activity Score (BVAS)
Birmingham Vasculitis Activity Score (BVAS) change from baseline by timepoint up to week 52. The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The total score on all 9 organ systems gives an indication of the disease activity of each patient at the time of scoring. Total scores range from 0 to 63, with higher scores indicating more active vasculitis.
Time frame: from baseline to end of DB period, 52 Weeks
Spirometry Change From Baseline by Timepoint up to Week 52: Pre-BD FEV1 (L)
Pre-bronchodilator (BD) Forced Expiratory Volume during first second (FEV1) change from baseline by timepoint up to week 52
Time frame: from baseline to end of DB period, 52 Weeks
Spirometry Change From Baseline by Timepoint up to Week 52: Pre-BD FVC (L)
Pre-bronchodilator (BD) Forced vital capacity (FVC) change from baseline by timepoint up to week 52
Time frame: from baseline to end of DB period, 52 Weeks
Change From Baseline in Vasculitis Damage Index (VDI)
Vasculitis Damage Index (VDI) change from baseline by timepoint up to week 52. The VDI is divided into 11 organ systems and records items of damage, due to vasculitis, treatment or unrelated, that have occurred since the onset of vasculitis. Completion of the form provides a numerical score, ranging from 0 to 64, with a higher score indicating more damage.
Time frame: from baseline to end of DB period, 52 Weeks
Change From Baseline in Asthma Control Questionnaire (6-item Version) (ACQ-6)
Asthma Control Questionnaire (6-item version) (ACQ-6) change from baseline by timepoint up to week 52. The ACQ-6 score is calculated by taking the mean of 6 equally weighted domains, with a range of 0 (well controlled) to 6 (extremely poorly controlled).
Time frame: from baseline to end of DB period, 52 Weeks
Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) Component: Physical Component Summary (PCS)
Short Form 36-item health survey (version 2, acute recall) (SF-36v2) component Physical Component Summary (PCS) change from baseline by timepoint up to week 52. PCS score ranges from 10.8 to 75.5, where a higher score indicates better health.
Time frame: from baseline to end of DB period, 52 Weeks
Change From Baseline in Short Form 36-item Health Survey (Version 2, Acute Recall) (SF-36v2) Component: Mental Component Summary (MCS)
Short Form 36-item health survey (version 2, acute recall) (SF-36v2) component Mental Component Summary (MCS) change from baseline by timepoint up to week 52. MCS score ranges from 5.6 to 69.7, where a higher score indicates better health.
Time frame: from baseline to end of DB period, 52 Weeks
Change From Baseline in Sino-nasal Outcome Test-22 (SNOT-22) Total Score
Sino-nasal Outcome Test-22 (SNOT-22) total score change from baseline by timepoint up to week 52. Patient reported symptom severity and symptom impact over the previous 2 weeks on 22 items are captured via a 6-point scale (0 = no problem to 5 = problem as bad as it can be). The total score is the sum of item scores and ranges from 0 to 110 (higher scores indicate poorer outcomes).
Time frame: from baseline to end of DB period, 52 Weeks
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Runny Nose
Sino-nasal Symptoms Questionnaire (SSQ) scores : symptom runny nose by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
Time frame: from baseline to end of DB period, 52 Weeks
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Post-nasal Discharge
Sino-nasal Symptoms Questionnaire (SSQ) scores : symptom Post-nasal discharge by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
Time frame: from baseline to end of DB period, 52 Weeks
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Facial Pain/Pressure
Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Facial pain/pressure by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
Time frame: from baseline to end of DB period, 52 Weeks
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Loss or Reduction in Sense of Taste/Smell
Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Loss or reduction in sense of taste/smell by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
Time frame: from baseline to end of DB period, 52 Weeks
Sino-nasal Symptoms Questionnaire (SSQ) Scores: Symptom Blockage/Congestion of Nose
Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Blockage/congestion of nose by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
Time frame: from baseline to end of DB period, 52 Weeks
Patient Global Impression of Severity (PGIS) Category
Patient Global Impression of Severity (PGIS) category by timepoint
Time frame: from baseline to end of DB period, 52 Weeks
Patient Global Impression of Change (PGIC) Category
Patient Global Impression of Change (PGIC) category by timepoint
Time frame: from baseline to week 4
WPAI-GH Endpoint, Change From Baseline by Timepoint: Absenteeism (%)
The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Subscale: Absenteeism (work time missed) (%) score, range 0-100.
Time frame: from baseline to end of DB period, 52 Weeks
WPAI-GH Endpoint, Change From Baseline by Timepoint up to Week 52: Subscale: Presenteeism (Impairment at Work) (%), Range 0-100.
The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Presenteeism (%) score.
Time frame: from baseline to end of DB period, 52 Weeks
WPAI-GH Endpoint, Change From Baseline by Timepoint: Work Productivity Loss (%)
The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Work productivity loss (%) score, range 0-100.
Time frame: from baseline to end of DB period, 52 Weeks
WPAI-GH Endpoint, Change From Baseline by Timepoint: Activity Impairment (%)
The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Activity impairment (%) score, range 0-100.
Time frame: from baseline to end of DB period, 52 Weeks
Absolute Eosinophil Count, Change From Baseline
Absolute eosinophil count, change from baseline by timepoint up to week 52
Time frame: from baseline to end of DB period, 52 Weeks
140 participants were randomized to receive treatment in study D3253C00001 (MANDARA) with benralizumab 30 mg or mepolizumab 300 mg. Of the 140 patients randomized, 140 (100%) received treatment with study drug. 70 (50%) patients received benralizumab 30 mg and 70 (50%) patients received mepolizumab 300 mg.
| Milestone | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| Started | 70 | 70 |
| Completed | 69 | 67 |
| Not completed | 1 | 3 |
| Withdrew: Other reasons or due to covid-19 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Milestone | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| Started | 66 | 62 |
| Completed | 0 | 0 |
| Not completed | 66 | 62 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 2 |
| Withdrew: Withdrawal by subject | 2 | 0 |
| Withdrew: Ongoing | 60 | 57 |
| Withdrew: Other reasons | 1 | 1 |
Percentage of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 4 mg/day (main remission definition) at both Weeks 36 and 48.
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| Number of Subjects Who Achieved Main Remission at Both Weeks 36 and 48 | 40 | 40 |
Supportive endpoint: Proportion of patients with relapsing or refractory EGPA, achieving remission, defined as BVAS = 0 and OCS dose ≤ 7.5 mg/day (supportive remission definition) at both Weeks 36 and 48.
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| Supportive Endpoint: Proportion of Subjects Who Achieved Supportive Remission at Both Weeks 36 and 48 | 55 | 52 |
Total accrued duration of remission for the following categories: 0 week, \> 0 to \< 12 week, 12 to \< 24 week, 24 to \< 36 week, ≥ 36 week.
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| main remission — 0 week | 9 | 15 |
| main remission — >0 to <12 weeks | 13 | 10 |
| main remission — 12 to <24 weeks | 8 | 8 |
| main remission — 24 to <36 weeks | 20 | 19 |
| main remission — >=36 weeks | 20 | 18 |
| supportive remission — 0 week | 2 | 4 |
| supportive remission — >0 to <12 weeks | 2 | 3 |
| supportive remission — 12 to <24 weeks | 5 | 4 |
| supportive remission — 24 to <36 weeks | 16 | 15 |
| supportive remission — >=36 weeks | 45 | 44 |
Total accrued duration of sustained remission for the following categories: 0 week, \> 0 to \< 12 week, 12 to \< 24 week, 24 to \< 36 week, ≥ 36 week.
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| sustained main remission — 0 week | 9 | 15 |
| sustained main remission — >0 to <12 weeks | 15 | 13 |
| sustained main remission — 12 to <24 weeks | 11 | 8 |
| sustained main remission — 24 to <36 weeks | 16 | 18 |
| sustained main remission — >=36 weeks | 19 | 16 |
| sustained supportive remission — 0 week | 2 | 4 |
| sustained supportive remission — >0 to <12 weeks | 5 | 6 |
| sustained supportive remission — 12 to <24 weeks | 8 | 10 |
| sustained supportive remission — 24 to <36 weeks | 18 | 14 |
| sustained supportive remission — >=36 weeks | 37 | 36 |
Time from randomization to first Eosinophilic Granulomatosis with Polyangiitis (EGPA) relapse, where relapse is defined as any of the following: * Active vasculitis (BVAS \> 0); OR * Active asthma symptoms and/or signs with a corresponding worsening in ACQ-6 score; OR * Active nasal and/or sinus disease, with a corresponding worsening in at least one of the sino-nasal symptom questions; warranting any of the following: * An increased dose of OCS therapy to \> 4 mg/day prednisolone total daily dose; OR * An increased dose or addition of immunosuppressive therapy; OR * Hospitalization related to EGPA worsening Calculated using the Kaplan-Meier technique.
| percentage of subjects | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| relapse-percent subject with at least 1 relapse by week 16 | 5.71 (2.18 to 14.51) | 4.29 (1.40 to 12.70) |
| relapse-percent subject with at least 1 relapse by week 32 | 17.14 (10.12 to 28.21) | 20.24 (12.52 to 31.77) |
| relapse-percent subject with at least 1 relapse by week 52 | 30.00 (20.71 to 42.21) | 29.10 (19.85 to 41.40) |
| major relapse-percent subject with at least 1 relapse by week 16 | 0 (0 to 0) | 0 (0 to 0) |
| major relapse-percent subject with at least 1 relapse by week 32 | 0 (0 to 0) | 0 (0 to 0) |
| major relapse-percent subject with at least 1 relapse by week 52 | 0 (0 to 0) | 2.94 (0.74 to 11.25) |
Annualized Eosinophilic Granulomatosis with Polyangiitis (EGPA) relapse rate through end of DB treatment period. The estimate of annualized relapse rate (relapses per year) and the corresponding 95% CIs were calculated using a negative binomial model. The response variable in the model is the number of relapses experienced by a subject up to Week 52. The logarithm of the subject's corresponding follow-up time up to Week 52 was used as an offset variable to adjust for subjects having different follow-up times during which the events occur. The covariates in the model include treatment arm, baseline dose of prednisone, baseline BVAS and region.
| relapses per year | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| Annualized Eosinophilic Granulomatosis With Polyangiitis (EGPA) Relapse Rate | 0.50 (0.30 to 0.83) | 0.49 (0.28 to 0.86) |
Average daily dose of prednisolone/prednisone and change from baseline during Week 48 through 52, or last 28 days prior to last double-blind assessment for those that withdrew
| mg | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| average daily dose | 3.01 ± 3.776 | 3.43 ± 4.124 |
| change from baseline of average daily dose | -8.08 ± 4.575 | -7.52 ± 7.070 |
Proportion of patients with average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: 0 mg; \>0 to ≤ 4 mg; \> 4 to ≤ 7.5 mg and \> 7.5 mg
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| 0 | 29 | 19 |
| >0 to <=4.0 mg | 19 | 30 |
| >4.0 to <=7.5 mg | 15 | 13 |
| >7.5 mg | 7 | 8 |
Percentage reduction from baseline in average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: no reduction or withdrawal from treatment; \< 25% reduction; 25 to \< 50% reduction; 50 to \<75% reduction; 75 to \< 100% reduction; 100% reduction.
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| no reduction or withdrawal from IP before week 48 | 3 | 7 |
| <25% reduction | 0 | 2 |
| 25 to <50% reduction | 8 | 9 |
| 50 to <75% reduction | 19 | 17 |
| 75 to <100% reduction | 11 | 17 |
| 100% reduction | 29 | 18 |
Proportion of subjects with reduction from baseline in average daily dose of prednisolone/prednisone during Week 48 through 52 in each category: \>= 50% reduction; 100% reduction; OCS dose \<= 4 mg/day.
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| >=50% reduction | 59 | 52 |
| 100% reduction | 29 | 18 |
| OCS dose <=4 mg/day | 48 | 49 |
Proportion of subjects who achieved any clinical benefit definition 1 (defined as any of the following: * Main remission at any time in DB period * \>= 50% reduction in OCS dose in Weeks 48 to 52 * EGPA relapse free in DB period) and subjects who achieved complete response definition 1 (defined as meeting all the definition 1 criteria above.)
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| any clinical benefit-definition 1 | 66 | 63 |
| Complete response - definition 1 | 43 | 39 |
Proportion of patients who have achieved remission within the first 24 weeks and remained in remission for remainder of the double-blind treatment period
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| main remission | 28 | 27 |
| supportive remission | 41 | 40 |
Birmingham Vasculitis Activity Score (BVAS) change from baseline by timepoint up to week 52. The BVAS form is divided into 9 organ-based systems, with each section including symptoms/signs that are typical of that particular organ involvement in systemic vasculitis. The total score on all 9 organ systems gives an indication of the disease activity of each patient at the time of scoring. Total scores range from 0 to 63, with higher scores indicating more active vasculitis.
| scores on a scale | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 4 | -1.19 (-1.62 to -0.76) | -1.14 (-1.57 to -0.70) |
| week 8 | -1.33 (-1.75 to -0.90) | -1.74 (-2.16 to -1.31) |
| week 12 | -1.79 (-2.03 to -1.55) | -1.66 (-1.90 to -1.42) |
| week 16 | -1.85 (-2.04 to -1.65) | -1.80 (-2.00 to -1.59) |
| week 20 | -1.73 (-2.01 to -1.44) | -1.82 (-2.10 to -1.53) |
| week 24 | -1.59 (-1.88 to -1.31) | -1.74 (-2.02 to -1.45) |
| week 28 | -1.94 (-2.09 to -1.79) | -1.95 (-2.10 to -1.80) |
| week 32 | -1.92 (-2.04 to -1.80) | -1.93 (-2.05 to -1.81) |
| week 36 | -1.98 (-2.29 to -1.66) | -1.65 (-1.98 to -1.33) |
| week 40 | -1.84 (-2.01 to -1.67) | -1.89 (-2.07 to -1.72) |
| week 44 | -1.84 (-2.00 to -1.68) | -1.96 (-2.13 to -1.80) |
| week 48 | -1.80 (-2.04 to -1.56) | -1.92 (-2.17 to -1.66) |
| week 52 | -1.85 (-2.37 to -1.34) | -1.32 (-1.84 to -0.80) |
Pre-bronchodilator (BD) Forced Expiratory Volume during first second (FEV1) change from baseline by timepoint up to week 52
| L | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 12 | 0.13 (0.0 to 0.2) | 0.11 (0.0 to 0.2) |
| week 24 | 0.11 (0.0 to 0.2) | 0.13 (0.0 to 0.2) |
| week 36 | 0.10 (-0.0 to 0.2) | 0.11 (0.0 to 0.2) |
| week 48 | 0.03 (-0.1 to 0.1) | 0.06 (-0.0 to 0.2) |
| week 52 | 0.06 (-0.0 to 0.2) | 0.01 (-0.1 to 0.1) |
Pre-bronchodilator (BD) Forced vital capacity (FVC) change from baseline by timepoint up to week 52
| L | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 12 | 0.13 (0.0 to 0.2) | 0.05 (-0.0 to 0.2) |
| week 24 | 0.09 (0.0 to 0.2) | 0.04 (-0.1 to 0.1) |
| week 36 | 0.05 (-0.0 to 0.1) | 0.03 (-0.1 to 0.1) |
| week 48 | 0.03 (-0.1 to 0.1) | 0.00 (-0.1 to 0.1) |
| week 52 | 0.01 (-0.1 to 0.1) | -0.04 (-0.2 to 0.1) |
Vasculitis Damage Index (VDI) change from baseline by timepoint up to week 52. The VDI is divided into 11 organ systems and records items of damage, due to vasculitis, treatment or unrelated, that have occurred since the onset of vasculitis. Completion of the form provides a numerical score, ranging from 0 to 64, with a higher score indicating more damage.
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 24 | 0.06 (-0.00 to 0.12) | 0.04 (-0.02 to 0.10) |
| week 52 | 0.13 (0.04 to 0.22) | 0.10 (0.01 to 0.20) |
Asthma Control Questionnaire (6-item version) (ACQ-6) change from baseline by timepoint up to week 52. The ACQ-6 score is calculated by taking the mean of 6 equally weighted domains, with a range of 0 (well controlled) to 6 (extremely poorly controlled).
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 1-4 | -0.34 (-0.47 to -0.21) | -0.31 (-0.44 to -0.18) |
| week 5-8 | -0.56 (-0.68 to -0.43) | -0.49 (-0.61 to -0.36) |
| week 9-12 | -0.55 (-0.68 to -0.42) | -0.52 (-0.65 to -0.39) |
| week 13-16 | -0.62 (-0.76 to -0.48) | -0.48 (-0.62 to -0.33) |
| week 17-20 | -0.59 (-0.75 to -0.43) | -0.47 (-0.63 to -0.31) |
| week 21-24 | -0.59 (-0.76 to -0.43) | -0.53 (-0.70 to -0.37) |
| week 25-28 | -0.65 (-0.80 to -0.49) | -0.49 (-0.64 to -0.33) |
| week 29-32 | -0.56 (-0.73 to -0.39) | -0.50 (-0.67 to -0.33) |
| week 33-36 | -0.57 (-0.73 to -0.41) | -0.55 (-0.71 to -0.39) |
| week 37-40 | -0.57 (-0.72 to -0.42) | -0.54 (-0.69 to -0.39) |
| week 41-44 | -0.58 (-0.73 to -0.43) | -0.60 (-0.75 to -0.45) |
| week 45-48 | -0.61 (-0.76 to -0.45) | -0.64 (-0.79 to -0.48) |
| week 49-52 | -0.57 (-0.72 to -0.41) | -0.61 (-0.77 to -0.46) |
Short Form 36-item health survey (version 2, acute recall) (SF-36v2) component Physical Component Summary (PCS) change from baseline by timepoint up to week 52. PCS score ranges from 10.8 to 75.5, where a higher score indicates better health.
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 1 | 0.68 (-0.4 to 1.7) | 0.88 (-0.2 to 1.9) |
| week 4 | 1.18 (-0.1 to 2.5) | 1.11 (-0.2 to 2.4) |
| week 8 | 1.56 (0.3 to 2.8) | 1.46 (0.2 to 2.7) |
| week 12 | 1.30 (-0.0 to 2.6) | 1.31 (-0.0 to 2.6) |
| week 16 | 1.24 (-0.2 to 2.7) | 1.85 (0.4 to 3.3) |
| week 28 | 1.54 (-0.0 to 3.1) | 2.12 (0.6 to 3.7) |
| week 40 | 1.73 (0.4 to 3.1) | 2.28 (0.9 to 3.6) |
| week 52 | 0.29 (-1.3 to 1.9) | 2.45 (0.8 to 4.0) |
Short Form 36-item health survey (version 2, acute recall) (SF-36v2) component Mental Component Summary (MCS) change from baseline by timepoint up to week 52. MCS score ranges from 5.6 to 69.7, where a higher score indicates better health.
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 1 | 0.90 (-0.7 to 2.5) | -0.13 (-1.7 to 1.5) |
| week 4 | 0.06 (-1.8 to 1.9) | 0.58 (-1.2 to 2.4) |
| week 8 | 0.64 (-1.3 to 2.6) | 1.05 (-0.9 to 3.0) |
| week 12 | 0.04 (-1.9 to 2.0) | 1.44 (-0.5 to 3.4) |
| week 16 | 0.29 (-1.8 to 2.3) | 2.18 (0.1 to 4.2) |
| week 28 | -0.03 (-2.0 to 1.9) | 2.03 (0.1 to 4.0) |
| week 40 | 0.77 (-1.5 to 3.0) | 2.39 (0.2 to 4.6) |
| week 52 | 1.13 (-1.1 to 3.4) | 2.19 (-0.1 to 4.4) |
Sino-nasal Outcome Test-22 (SNOT-22) total score change from baseline by timepoint up to week 52. Patient reported symptom severity and symptom impact over the previous 2 weeks on 22 items are captured via a 6-point scale (0 = no problem to 5 = problem as bad as it can be). The total score is the sum of item scores and ranges from 0 to 110 (higher scores indicate poorer outcomes).
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 4 | -4.34 (-7.2 to -1.5) | -4.32 (-7.2 to -1.5) |
| week 8 | -5.79 (-8.8 to -2.8) | -6.42 (-9.4 to -3.4) |
| week 12 | -5.30 (-8.5 to -2.1) | -6.35 (-9.5 to -3.2) |
| week 16 | -6.04 (-9.2 to -2.9) | -6.04 (-9.2 to -2.9) |
| week 28 | -7.89 (-11.0 to -4.8) | -7.59 (-10.7 to -4.5) |
| week 40 | -5.05 (-8.2 to -1.9) | -8.33 (-11.6 to -5.1) |
| week 52 | -5.98 (-9.3 to -2.7) | -6.35 (-9.7 to -3.0) |
Sino-nasal Symptoms Questionnaire (SSQ) scores : symptom runny nose by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| baseline | 1.0 ± 0.85 | 1.2 ± 1.00 |
| week 1-4 | 1.4 ± 0.95 | 1.2 ± 0.97 |
| week 5-8 | 1.3 ± 0.92 | 1.0 ± 0.86 |
| week 9-12 | 1.4 ± 1.00 | 1.0 ± 0.88 |
| week 13-16 | 1.4 ± 0.99 | 1.2 ± 0.92 |
| week 17-20 | 1.3 ± 0.98 | 1.1 ± 0.96 |
| week 21-24 | 1.3 ± 0.88 | 1.2 ± 0.86 |
| week 25-28 | 1.1 ± 0.95 | 1.2 ± 0.90 |
| week 29-32 | 1.2 ± 0.90 | 1.1 ± 0.99 |
| week 33-36 | 1.3 ± 0.87 | 1.0 ± 0.90 |
| week 37-40 | 1.3 ± 0.96 | 1.0 ± 0.87 |
| week 41-44 | 1.1 ± 0.86 | 0.9 ± 0.76 |
| week 45-48 | 1.3 ± 0.98 | 0.9 ± 0.87 |
| week 49-52 | 1.2 ± 0.98 | 1.0 ± 0.96 |
Sino-nasal Symptoms Questionnaire (SSQ) scores : symptom Post-nasal discharge by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| baseline | 1.1 ± 1.00 | 1.2 ± 1.06 |
| week 1-4 | 1.4 ± 0.88 | 1.3 ± 1.00 |
| week 5-8 | 1.2 ± 0.94 | 1.2 ± 0.85 |
| week 9-12 | 1.2 ± 1.01 | 1.2 ± 0.98 |
| week 13-16 | 1.2 ± 0.96 | 1.2 ± 0.94 |
| week 17-20 | 1.2 ± 0.99 | 1.3 ± 0.99 |
| week 21-24 | 1.2 ± 0.93 | 1.2 ± 0.98 |
| week 25-28 | 1.1 ± 1.05 | 1.1 ± 0.88 |
| week 29-32 | 1.1 ± 0.97 | 1.1 ± 0.99 |
| week 33-36 | 1.1 ± 0.88 | 1.0 ± 0.95 |
| week 37-40 | 1.2 ± 0.96 | 0.9 ± 0.81 |
| week 41-44 | 1.1 ± 1.05 | 0.9 ± 0.83 |
| week 45-48 | 1.1 ± 1.03 | 1.0 ± 0.89 |
| week 49-52 | 1.1 ± 0.96 | 1.0 ± 0.95 |
Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Facial pain/pressure by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| baseline | 0.7 ± 0.95 | 0.6 ± 0.94 |
| week 1-4 | 0.9 ± 0.97 | 0.8 ± 0.99 |
| week 5-8 | 0.9 ± 1.08 | 0.8 ± 0.93 |
| week 9-12 | 0.9 ± 1.01 | 0.8 ± 0.88 |
| week 13-16 | 0.8 ± 0.93 | 0.6 ± 0.80 |
| week 17-20 | 0.9 ± 0.97 | 0.7 ± 0.93 |
| week 21-24 | 0.8 ± 0.88 | 0.6 ± 0.81 |
| week 25-28 | 0.7 ± 0.95 | 0.6 ± 0.89 |
| week 29-32 | 0.7 ± 0.89 | 0.6 ± 0.90 |
| week 33-36 | 0.6 ± 0.86 | 0.6 ± 0.89 |
| week 37-40 | 0.8 ± 1.01 | 0.6 ± 0.82 |
| week 41-44 | 0.7 ± 0.92 | 0.6 ± 0.82 |
| week 45-48 | 0.7 ± 0.90 | 0.7 ± 0.98 |
| week 49-52 | 0.7 ± 0.90 | 0.6 ± 0.87 |
Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Loss or reduction in sense of taste/smell by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| baseline | 1.3 ± 1.32 | 1.2 ± 1.43 |
| week 1-4 | 1.3 ± 1.36 | 1.2 ± 1.45 |
| week 5-8 | 1.2 ± 1.28 | 1.1 ± 1.35 |
| week 9-12 | 1.2 ± 1.29 | 1.0 ± 1.36 |
| week 13-16 | 1.3 ± 1.32 | 1.1 ± 1.41 |
| week 17-20 | 1.3 ± 1.36 | 1.1 ± 1.32 |
| week 21-24 | 1.4 ± 1.44 | 1.2 ± 1.33 |
| week 25-28 | 1.3 ± 1.39 | 1.1 ± 1.37 |
| week 29-32 | 1.4 ± 1.34 | 1.0 ± 1.38 |
| week 33-36 | 1.4 ± 1.39 | 1.1 ± 1.35 |
| week 37-40 | 1.5 ± 1.38 | 1.1 ± 1.31 |
| week 41-44 | 1.5 ± 1.43 | 1.0 ± 1.29 |
| week 45-48 | 1.5 ± 1.44 | 1.1 ± 1.36 |
| week 49-52 | 1.5 ± 1.40 | 1.1 ± 1.35 |
Sino-nasal Symptoms Questionnaire (SSQ) scores: symptom Blockage/congestion of nose by timepoint. For the SSQ, participants rate each symptom against the following categories: very severe, severe, moderate, mild, none. Higher scores indicate greater severity (0 = none to 4 = very severe).
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| baseline | 1.3 ± 1.07 | 1.4 ± 1.15 |
| week 1-4 | 1.5 ± 0.99 | 1.4 ± 0.96 |
| week 5-8 | 1.5 ± 0.96 | 1.4 ± 1.03 |
| week 9-12 | 1.5 ± 0.90 | 1.3 ± 1.00 |
| week 13-16 | 1.6 ± 1.14 | 1.4 ± 1.09 |
| week 17-20 | 1.7 ± 1.12 | 1.4 ± 1.04 |
| week 21-24 | 1.6 ± 1.06 | 1.3 ± 1.05 |
| week 25-28 | 1.4 ± 1.03 | 1.4 ± 1.03 |
| week 29-32 | 1.5 ± 0.99 | 1.4 ± 1.13 |
| week 33-36 | 1.5 ± 0.92 | 1.3 ± 1.09 |
| week 37-40 | 1.6 ± 1.01 | 1.3 ± 1.14 |
| week 41-44 | 1.5 ± 1.08 | 1.2 ± 0.96 |
| week 45-48 | 1.5 ± 1.13 | 1.3 ± 1.11 |
| week 49-52 | 1.5 ± 1.07 | 1.3 ± 1.03 |
Patient Global Impression of Severity (PGIS) category by timepoint
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| baseline — No symptoms | 8 | 2 |
| baseline — Very mild | 8 | 19 |
| baseline — Mild | 18 | 16 |
| baseline — Moderate | 28 | 26 |
| baseline — Severe | 7 | 5 |
| baseline — Very severe | 1 | 2 |
| baseline — Missing | 0 | 0 |
| week 1 — No symptoms | 4 | 4 |
| week 1 — Very mild | 15 | 15 |
| week 1 — Mild | 21 | 16 |
| week 1 — Moderate | 24 | 26 |
| week 1 — Severe | 4 | 6 |
| week 1 — Very severe | 1 | 0 |
| week 1 — Missing | 1 | 3 |
| week 2 — No symptoms | 12 | 5 |
| week 2 — Very mild | 14 | 27 |
| week 2 — Mild | 21 | 11 |
| week 2 — Moderate | 20 | 18 |
| week 2 — Severe | 1 | 3 |
| week 2 — Very severe | 0 | 1 |
| week 2 — Missing | 2 | 5 |
| week 3 — No symptoms | 9 | 8 |
| week 3 — Very mild | 23 | 24 |
| week 3 — Mild | 16 | 19 |
| week 3 — Moderate | 18 | 13 |
| week 3 — Severe | 2 | 3 |
| week 3 — Very severe | 0 | 0 |
| week 3 — Missing | 2 | 3 |
| week 4 — No symptoms | 6 | 8 |
| week 4 — Very mild | 17 | 20 |
| week 4 — Mild | 15 | 13 |
| week 4 — Moderate | 26 | 23 |
| week 4 — Severe | 3 | 5 |
| week 4 — Very severe | 1 | 0 |
| week 4 — Missing | 2 | 1 |
| week 5 — No symptoms | 12 | 6 |
| week 5 — Very mild | 20 | 31 |
| week 5 — Mild | 24 | 15 |
| week 5 — Moderate | 12 | 14 |
| week 5 — Severe | 0 | 3 |
| week 5 — Very severe | 0 | 0 |
| week 5 — Missing | 2 | 1 |
| week 6 — No symptoms | 8 | 9 |
| week 6 — Very mild | 29 | 33 |
| week 6 — Mild | 18 | 13 |
| week 6 — Moderate | 13 | 9 |
| week 6 — Severe | 1 | 1 |
| week 6 — Very severe | 0 | 2 |
| week 6 — Missing | 1 | 3 |
| week 7 — No symptoms | 8 | 12 |
| week 7 — Very mild | 25 | 23 |
| week 7 — Mild | 18 | 20 |
| week 7 — Moderate | 14 | 10 |
| week 7 — Severe | 3 | 1 |
| week 7 — Very severe | 0 | 1 |
| week 7 — Missing | 2 | 3 |
| week 8 — No symptoms | 4 | 5 |
| week 8 — Very mild | 18 | 24 |
| week 8 — Mild | 18 | 15 |
| week 8 — Moderate | 21 | 20 |
| week 8 — Severe | 6 | 3 |
| week 8 — Very severe | 1 | 2 |
| week 8 — Missing | 2 | 1 |
| week 9 — No symptoms | 7 | 14 |
| week 9 — Very mild | 26 | 22 |
| week 9 — Mild | 17 | 17 |
| week 9 — Moderate | 14 | 13 |
| week 9 — Severe | 4 | 2 |
| week 9 — Very severe | 0 | 0 |
| week 9 — Missing | 2 | 2 |
| week 10 — No symptoms | 7 | 11 |
| week 10 — Very mild | 21 | 24 |
| week 10 — Mild | 24 | 22 |
| week 10 — Moderate | 13 | 7 |
| week 10 — Severe | 1 | 2 |
| week 10 — Very severe | 2 | 0 |
| week 10 — Missing | 2 | 4 |
| week 11 — No symptoms | 7 | 13 |
| week 11 — Very mild | 27 | 24 |
| week 11 — Mild | 17 | 15 |
| week 11 — Moderate | 14 | 15 |
| week 11 — Severe | 2 | 1 |
| week 11 — Very severe | 1 | 0 |
| week 11 — Missing | 2 | 2 |
| week 12 — No symptoms | 6 | 8 |
| week 12 — Very mild | 18 | 20 |
| week 12 — Mild | 19 | 16 |
| week 12 — Moderate | 17 | 20 |
| week 12 — Severe | 6 | 4 |
| week 12 — Very severe | 2 | 0 |
| week 12 — Missing | 2 | 2 |
| week 13 — No symptoms | 6 | 9 |
| week 13 — Very mild | 26 | 24 |
| week 13 — Mild | 22 | 18 |
| week 13 — Moderate | 11 | 15 |
| week 13 — Severe | 2 | 3 |
| week 13 — Very severe | 1 | 0 |
| week 13 — Missing | 2 | 1 |
| week 14 — No symptoms | 6 | 11 |
| week 14 — Very mild | 29 | 24 |
| week 14 — Mild | 15 | 15 |
| week 14 — Moderate | 15 | 15 |
| week 14 — Severe | 2 | 1 |
| week 14 — Very severe | 0 | 1 |
| week 14 — Missing | 3 | 3 |
| week 15 — No symptoms | 6 | 11 |
| week 15 — Very mild | 31 | 23 |
| week 15 — Mild | 12 | 17 |
| week 15 — Moderate | 16 | 16 |
| week 15 — Severe | 3 | 1 |
| week 15 — Very severe | 0 | 0 |
| week 15 — Missing | 2 | 2 |
| week 16 — No symptoms | 3 | 5 |
| week 16 — Very mild | 23 | 21 |
| week 16 — Mild | 17 | 26 |
| week 16 — Moderate | 19 | 13 |
| week 16 — Severe | 5 | 1 |
| week 16 — Very severe | 1 | 1 |
| week 16 — Missing | 2 | 3 |
| week 17 — No symptoms | 13 | 6 |
| week 17 — Very mild | 23 | 28 |
| week 17 — Mild | 14 | 19 |
| week 17 — Moderate | 19 | 11 |
| week 17 — Severe | 1 | 2 |
| week 17 — Very severe | 0 | 1 |
| week 17 — Missing | 0 | 3 |
| week 18 — No symptoms | 7 | 7 |
| week 18 — Very mild | 27 | 28 |
| week 18 — Mild | 14 | 13 |
| week 18 — Moderate | 18 | 18 |
| week 18 — Severe | 0 | 2 |
| week 18 — Very severe | 2 | 0 |
| week 18 — Missing | 2 | 2 |
| week 19 — No symptoms | 7 | 11 |
| week 19 — Very mild | 27 | 25 |
| week 19 — Mild | 14 | 17 |
| week 19 — Moderate | 14 | 15 |
| week 19 — Severe | 5 | 0 |
| week 19 — Very severe | 2 | 1 |
| week 19 — Missing | 1 | 1 |
| week 20 — No symptoms | 8 | 13 |
| week 20 — Very mild | 22 | 20 |
| week 20 — Mild | 18 | 21 |
| week 20 — Moderate | 14 | 11 |
| week 20 — Severe | 7 | 1 |
| week 20 — Very severe | 0 | 1 |
| week 20 — Missing | 1 | 3 |
| week 21 — No symptoms | 7 | 15 |
| week 21 — Very mild | 26 | 24 |
| week 21 — Mild | 13 | 12 |
| week 21 — Moderate | 17 | 13 |
| week 21 — Severe | 5 | 2 |
| week 21 — Very severe | 1 | 0 |
| week 21 — Missing | 1 | 4 |
| week 22 — No symptoms | 13 | 12 |
| week 22 — Very mild | 19 | 24 |
| week 22 — Mild | 19 | 16 |
| week 22 — Moderate | 16 | 12 |
| week 22 — Severe | 3 | 1 |
| week 22 — Very severe | 0 | 0 |
| week 22 — Missing | 0 | 5 |
| week 23 — No symptoms | 8 | 13 |
| week 23 — Very mild | 24 | 24 |
| week 23 — Mild | 20 | 19 |
| week 23 — Moderate | 14 | 13 |
| week 23 — Severe | 1 | 1 |
| week 23 — Very severe | 2 | 0 |
| week 23 — Missing | 1 | 0 |
| week 24 — No symptoms | 7 | 13 |
| week 24 — Very mild | 25 | 22 |
| week 24 — Mild | 20 | 16 |
| week 24 — Moderate | 14 | 16 |
| week 24 — Severe | 3 | 2 |
| week 24 — Very severe | 0 | 0 |
| week 24 — Missing | 1 | 1 |
| week 25 — No symptoms | 11 | 13 |
| week 25 — Very mild | 25 | 22 |
| week 25 — Mild | 19 | 17 |
| week 25 — Moderate | 10 | 14 |
| week 25 — Severe | 4 | 0 |
| week 25 — Very severe | 0 | 0 |
| week 25 — Missing | 1 | 4 |
| week 26 — No symptoms | 12 | 13 |
| week 26 — Very mild | 25 | 22 |
| week 26 — Mild | 17 | 14 |
| week 26 — Moderate | 11 | 15 |
| week 26 — Severe | 3 | 2 |
| week 26 — Very severe | 1 | 1 |
| week 26 — Missing | 1 | 3 |
| week 27 — No symptoms | 10 | 15 |
| week 27 — Very mild | 28 | 21 |
| week 27 — Mild | 16 | 17 |
| week 27 — Moderate | 15 | 10 |
| week 27 — Severe | 0 | 2 |
| week 27 — Very severe | 1 | 0 |
| week 27 — Missing | 0 | 5 |
| week 28 — No symptoms | 6 | 9 |
| week 28 — Very mild | 21 | 21 |
| week 28 — Mild | 23 | 18 |
| week 28 — Moderate | 14 | 16 |
| week 28 — Severe | 4 | 2 |
| week 28 — Very severe | 1 | 0 |
| week 28 — Missing | 1 | 4 |
| week 29 — No symptoms | 6 | 12 |
| week 29 — Very mild | 28 | 21 |
| week 29 — Mild | 17 | 19 |
| week 29 — Moderate | 15 | 10 |
| week 29 — Severe | 2 | 3 |
| week 29 — Very severe | 0 | 0 |
| week 29 — Missing | 2 | 5 |
| week 30 — No symptoms | 7 | 18 |
| week 30 — Very mild | 22 | 16 |
| week 30 — Mild | 25 | 18 |
| week 30 — Moderate | 11 | 9 |
| week 30 — Severe | 3 | 2 |
| week 30 — Very severe | 0 | 1 |
| week 30 — Missing | 2 | 6 |
| week 31 — No symptoms | 8 | 16 |
| week 31 — Very mild | 22 | 20 |
| week 31 — Mild | 18 | 17 |
| week 31 — Moderate | 16 | 11 |
| week 31 — Severe | 3 | 2 |
| week 31 — Very severe | 0 | 0 |
| week 31 — Missing | 3 | 4 |
| week 32 — No symptoms | 6 | 15 |
| week 32 — Very mild | 25 | 20 |
| week 32 — Mild | 17 | 20 |
| week 32 — Moderate | 16 | 8 |
| week 32 — Severe | 3 | 3 |
| week 32 — Very severe | 1 | 0 |
| week 32 — Missing | 2 | 4 |
| week 33 — No symptoms | 6 | 17 |
| week 33 — Very mild | 23 | 20 |
| week 33 — Mild | 22 | 14 |
| week 33 — Moderate | 14 | 13 |
| week 33 — Severe | 2 | 1 |
| week 33 — Very severe | 0 | 0 |
| week 33 — Missing | 3 | 5 |
| week 34 — No symptoms | 8 | 14 |
| week 34 — Very mild | 27 | 18 |
| week 34 — Mild | 17 | 20 |
| week 34 — Moderate | 13 | 11 |
| week 34 — Severe | 2 | 2 |
| week 34 — Very severe | 1 | 0 |
| week 34 — Missing | 2 | 5 |
| week 35 — No symptoms | 10 | 16 |
| week 35 — Very mild | 25 | 20 |
| week 35 — Mild | 16 | 18 |
| week 35 — Moderate | 13 | 10 |
| week 35 — Severe | 2 | 2 |
| week 35 — Very severe | 1 | 0 |
| week 35 — Missing | 3 | 4 |
| week 36 — No symptoms | 7 | 15 |
| week 36 — Very mild | 26 | 22 |
| week 36 — Mild | 15 | 17 |
| week 36 — Moderate | 18 | 12 |
| week 36 — Severe | 1 | 1 |
| week 36 — Very severe | 1 | 0 |
| week 36 — Missing | 2 | 3 |
| week 37 — No symptoms | 5 | 17 |
| week 37 — Very mild | 28 | 21 |
| week 37 — Mild | 18 | 14 |
| week 37 — Moderate | 15 | 11 |
| week 37 — Severe | 1 | 2 |
| week 37 — Very severe | 0 | 1 |
| week 37 — Missing | 3 | 4 |
| week 38 — No symptoms | 7 | 17 |
| week 38 — Very mild | 25 | 24 |
| week 38 — Mild | 16 | 10 |
| week 38 — Moderate | 16 | 12 |
| week 38 — Severe | 1 | 3 |
| week 38 — Very severe | 0 | 0 |
| week 38 — Missing | 5 | 4 |
| week 39 — No symptoms | 5 | 19 |
| week 39 — Very mild | 30 | 23 |
| week 39 — Mild | 14 | 13 |
| week 39 — Moderate | 16 | 9 |
| week 39 — Severe | 1 | 2 |
| week 39 — Very severe | 0 | 0 |
| week 39 — Missing | 4 | 4 |
| week 40 — No symptoms | 2 | 10 |
| week 40 — Very mild | 20 | 18 |
| week 40 — Mild | 24 | 18 |
| week 40 — Moderate | 18 | 14 |
| week 40 — Severe | 2 | 3 |
| week 40 — Very severe | 0 | 1 |
| week 40 — Missing | 4 | 6 |
| week 41 — No symptoms | 6 | 17 |
| week 41 — Very mild | 25 | 23 |
| week 41 — Mild | 20 | 16 |
| week 41 — Moderate | 13 | 4 |
| week 41 — Severe | 1 | 5 |
| week 41 — Very severe | 0 | 0 |
| week 41 — Missing | 5 | 5 |
| week 42 — No symptoms | 7 | 15 |
| week 42 — Very mild | 23 | 26 |
| week 42 — Mild | 18 | 17 |
| week 42 — Moderate | 15 | 4 |
| week 42 — Severe | 2 | 3 |
| week 42 — Very severe | 0 | 0 |
| week 42 — Missing | 5 | 5 |
| week 43 — No symptoms | 9 | 15 |
| week 43 — Very mild | 17 | 27 |
| week 43 — Mild | 21 | 16 |
| week 43 — Moderate | 13 | 6 |
| week 43 — Severe | 1 | 2 |
| week 43 — Very severe | 2 | 0 |
| week 43 — Missing | 7 | 4 |
| week 44 — No symptoms | 6 | 16 |
| week 44 — Very mild | 24 | 23 |
| week 44 — Mild | 19 | 17 |
| week 44 — Moderate | 14 | 6 |
| week 44 — Severe | 2 | 3 |
| week 44 — Very severe | 1 | 0 |
| week 44 — Missing | 4 | 5 |
| week 45 — No symptoms | 8 | 16 |
| week 45 — Very mild | 21 | 26 |
| week 45 — Mild | 22 | 14 |
| week 45 — Moderate | 13 | 8 |
| week 45 — Severe | 2 | 3 |
| week 45 — Very severe | 0 | 0 |
| week 45 — Missing | 4 | 3 |
| week 46 — No symptoms | 9 | 16 |
| week 46 — Very mild | 23 | 27 |
| week 46 — Mild | 13 | 15 |
| week 46 — Moderate | 17 | 7 |
| week 46 — Severe | 3 | 2 |
| week 46 — Very severe | 1 | 0 |
| week 46 — Missing | 4 | 3 |
| week 47 — No symptoms | 6 | 17 |
| week 47 — Very mild | 25 | 27 |
| week 47 — Mild | 16 | 11 |
| week 47 — Moderate | 16 | 7 |
| week 47 — Severe | 2 | 2 |
| week 47 — Very severe | 1 | 0 |
| week 47 — Missing | 4 | 6 |
| week 48 — No symptoms | 11 | 17 |
| week 48 — Very mild | 26 | 23 |
| week 48 — Mild | 14 | 13 |
| week 48 — Moderate | 15 | 9 |
| week 48 — Severe | 1 | 4 |
| week 48 — Very severe | 2 | 0 |
| week 48 — Missing | 1 | 4 |
| week 49 — No symptoms | 12 | 14 |
| week 49 — Very mild | 20 | 25 |
| week 49 — Mild | 18 | 16 |
| week 49 — Moderate | 15 | 10 |
| week 49 — Severe | 2 | 0 |
| week 49 — Very severe | 0 | 0 |
| week 49 — Missing | 3 | 5 |
| week 50 — No symptoms | 10 | 16 |
| week 50 — Very mild | 29 | 26 |
| week 50 — Mild | 12 | 13 |
| week 50 — Moderate | 15 | 8 |
| week 50 — Severe | 1 | 0 |
| week 50 — Very severe | 1 | 1 |
| week 50 — Missing | 2 | 6 |
| week 51 — No symptoms | 12 | 15 |
| week 51 — Very mild | 18 | 25 |
| week 51 — Mild | 16 | 16 |
| week 51 — Moderate | 16 | 3 |
| week 51 — Severe | 2 | 2 |
| week 51 — Very severe | 0 | 0 |
| week 51 — Missing | 6 | 9 |
| week 52 — No symptoms | 4 | 11 |
| week 52 — Very mild | 20 | 18 |
| week 52 — Mild | 14 | 19 |
| week 52 — Moderate | 16 | 12 |
| week 52 — Severe | 5 | 1 |
| week 52 — Very severe | 2 | 0 |
| week 52 — Missing | 9 | 9 |
Patient Global Impression of Change (PGIC) category by timepoint
| Participants | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 1 — Much better | 2 | 0 |
| week 1 — Moderately better | 4 | 1 |
| week 1 — A little better | 15 | 21 |
| week 1 — About the same | 45 | 39 |
| week 1 — A little worse | 2 | 5 |
| week 1 — Moderately worse | 1 | 0 |
| week 1 — Much worse | 0 | 0 |
| week 1 — Missing | 1 | 4 |
| week 2 — Much better | 7 | 2 |
| week 2 — Moderately better | 7 | 6 |
| week 2 — A little better | 14 | 22 |
| week 2 — About the same | 38 | 33 |
| week 2 — A little worse | 2 | 1 |
| week 2 — Moderately worse | 0 | 0 |
| week 2 — Much worse | 0 | 1 |
| week 2 — Missing | 2 | 5 |
| week 3 — Much better | 7 | 3 |
| week 3 — Moderately better | 7 | 7 |
| week 3 — A little better | 15 | 27 |
| week 3 — About the same | 36 | 27 |
| week 3 — A little worse | 2 | 1 |
| week 3 — Moderately worse | 1 | 0 |
| week 3 — Much worse | 0 | 2 |
| week 3 — Missing | 2 | 3 |
| week 4 — Much better | 6 | 2 |
| week 4 — Moderately better | 5 | 12 |
| week 4 — A little better | 17 | 20 |
| week 4 — About the same | 35 | 31 |
| week 4 — A little worse | 4 | 2 |
| week 4 — Moderately worse | 0 | 1 |
| week 4 — Much worse | 0 | 1 |
| week 4 — Missing | 3 | 1 |
The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Subscale: Absenteeism (work time missed) (%) score, range 0-100.
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 4 | -1.24 ± 22.167 | -5.46 ± 25.387 |
| week 8 | 0.71 ± 21.429 | -7.75 ± 28.680 |
| week 12 | 6.59 ± 23.328 | -8.88 ± 30.513 |
| week 16 | 12.43 ± 28.205 | -7.94 ± 36.950 |
| week 28 | 4.16 ± 17.279 | -3.59 ± 40.441 |
| week 40 | -1.29 ± 17.181 | -5.02 ± 35.641 |
| week 52 | 9.02 ± 23.971 | -10.99 ± 40.272 |
The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Presenteeism (%) score.
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 4 | -7.42 ± 15.268 | 0.36 ± 16.439 |
| week 8 | -2.58 ± 15.485 | 6.43 ± 14.457 |
| week 12 | -2.00 ± 12.247 | 3.20 ± 20.355 |
| week 16 | 2.59 ± 22.290 | 2.31 ± 17.043 |
| week 28 | -2.41 ± 19.022 | 3.46 ± 22.793 |
| week 40 | -3.91 ± 17.252 | 0.43 ± 10.215 |
| week 52 | 4.80 ± 34.535 | -6.19 ± 18.568 |
The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Work productivity loss (%) score, range 0-100.
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 4 | -7.35 ± 22.397 | 2.14 ± 14.775 |
| week 8 | -0.53 ± 23.935 | 6.26 ± 19.154 |
| week 12 | 1.47 ± 19.235 | 1.24 ± 24.149 |
| week 16 | 8.09 ± 31.026 | 5.31 ± 23.864 |
| week 28 | 0.05 ± 25.844 | 6.87 ± 24.114 |
| week 40 | -3.02 ± 23.350 | 0.67 ± 14.140 |
| week 52 | 5.82 ± 33.761 | -4.47 ± 27.803 |
The Work Productivity and Activity Impairment questionnaire (WPAI-GH) has 6 questions which address absenteeism, presenteeism (reduced effectiveness while working), overall work productivity loss (absenteeism plus presenteeism), and activity impairment for the 7 days prior to the assessment. WPAI outcomes are presented as impairment percentages (a higher percentage indicating greater impairment and less productivity). Activity impairment (%) score, range 0-100.
| score | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 4 | -3.97 ± 20.815 | -3.38 ± 19.745 |
| week 8 | -3.53 ± 21.144 | -4.71 ± 23.466 |
| week 12 | -4.56 ± 20.620 | -3.97 ± 20.453 |
| week 16 | -3.24 ± 21.402 | -6.42 ± 25.268 |
| week 28 | -4.41 ± 22.419 | -6.31 ± 27.419 |
| week 40 | -7.58 ± 20.234 | -4.46 ± 20.235 |
| week 52 | -3.28 ± 27.083 | -7.78 ± 25.492 |
Absolute eosinophil count, change from baseline by timepoint up to week 52
| cells*10^9/L | Benralizumab 30 mg | Mepolizumab 300 mg |
|---|---|---|
| week 1 | 0.15 (0.12 to 0.18) | 0.39 (0.32 to 0.47) |
| week 4 | 0.14 (0.12 to 0.17) | 0.30 (0.25 to 0.36) |
| week 8 | 0.10 (0.08 to 0.11) | 0.23 (0.20 to 0.28) |
| week 12 | 0.11 (0.09 to 0.13) | 0.25 (0.20 to 0.30) |
| week 16 | 0.11 (0.09 to 0.13) | 0.24 (0.20 to 0.29) |
| week 20 | 0.10 (0.08 to 0.12) | 0.23 (0.19 to 0.28) |
| week 24 | 0.14 (0.12 to 0.17) | 0.24 (0.20 to 0.29) |
| week 25 | 0.14 (0.11 to 0.17) | 0.23 (0.19 to 0.28) |
| week 28 | 0.10 (0.08 to 0.12) | 0.24 (0.20 to 0.29) |
| week 32 | 0.12 (0.10 to 0.14) | 0.22 (0.18 to 0.27) |
| week 36 | 0.11 (0.09 to 0.14) | 0.26 (0.21 to 0.31) |
| week 40 | 0.09 (0.08 to 0.11) | 0.22 (0.18 to 0.27) |
| week 44 | 0.10 (0.09 to 0.13) | 0.24 (0.20 to 0.29) |
| week 48 | 0.10 (0.08 to 0.13) | 0.24 (0.19 to 0.29) |
| week 52 | 0.10 (0.08 to 0.12) | 0.26 (0.21 to 0.32) |
Collected over Double-blind Treatment Period: From first dose of study drug until end of Double-blind period, up to 52 weeks. Open-label Extension Period: From the end of the Double-blind period (week 53) to the data cut-off date (10AUG2023), up to 138 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra 30 mg - DB | 0/70 (0%) | 4/70 (5.7%) | 46/70 (65.7%) |
| Mepo 300 mg - DB | 0/70 (0%) | 9/70 (12.9%) | 56/70 (80%) |
| Benra 30 mg - OLE | 0/66 (0%) | 10/66 (15.2%) | 43/66 (65.2%) |
| Mepo 300 mg Switched to Benra 30 mg - OLE | 1/62 (1.6%) | 13/62 (21%) | 46/62 (74.2%) |
| Event | Benra 30 mg - DB | Mepo 300 mg - DB | Benra 30 mg - OLE | Mepo 300 mg Switched to Benra 30 mg - OLE |
|---|---|---|---|---|
| Eosinophilic granulomatosis with polyangiitisImmune system disorders | 0/70 | 0/70 | 1/66 | 2/62 |
| Adrenal insufficiencyEndocrine disorders | 0/70 | 0/70 | 0/66 | 2/62 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/70 | 2/70 | 0/66 | 0/62 |
| AppendicitisInfections and infestations | 0/70 | 1/70 | 0/66 | 1/62 |
| CellulitisInfections and infestations | 0/70 | 0/70 | 1/66 | 1/62 |
| Clostridium difficile infectionInfections and infestations | 0/70 | 0/70 | 0/66 | 1/62 |
| Klebsiella urinary tract infectionInfections and infestations | 0/70 | 0/70 | 0/66 | 1/62 |
| Pneumonia viralInfections and infestations | 0/70 | 0/70 | 0/66 | 1/62 |
| Respiratory tract infectionInfections and infestations | 0/70 | 0/70 | 0/66 | 1/62 |
| Upper respiratory tract infectionInfections and infestations | 0/70 | 0/70 | 0/66 | 1/62 |
| Event | Benra 30 mg - DB | Mepo 300 mg - DB | Benra 30 mg - OLE | Mepo 300 mg Switched to Benra 30 mg - OLE |
|---|---|---|---|---|
| COVID-19Infections and infestations | 14/70 | 18/70 | 22/66 | 27/62 |
| SinusitisInfections and infestations | 5/70 | 8/70 | 14/66 | 4/62 |
| NasopharyngitisInfections and infestations | 6/70 | 10/70 | 6/66 | 11/62 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/70 | 8/70 | 3/66 | 1/62 |
| HeadacheNervous system disorders | 12/70 | 11/70 | 1/66 | 4/62 |
| BronchitisInfections and infestations | 4/70 | 5/70 | 7/66 | 2/62 |
| Influenza like illnessGeneral disorders | 4/70 | 3/70 | 7/66 | 4/62 |
| Viral upper respiratory tract infectionInfections and infestations | 1/70 | 6/70 | 1/66 | 2/62 |
| NauseaGastrointestinal disorders | 1/70 | 6/70 | 0/66 | 0/62 |
| AstheniaGeneral disorders | 6/70 | 0/70 | 0/66 | 1/62 |
All participants who were randomized and received any IP were included in the full analysis set.
| Age, Continuous(years) | Benralizumab 30 mg | Mepolizumab 300 mg | Total |
|---|---|---|---|
| Mean | 52.0 ± 13.90 | 52.7 ± 14.38 | 52.3 ± 14.10 |
| Age, Customized(participants) | Benralizumab 30 mg | Mepolizumab 300 mg | Total |
|---|---|---|---|
| >= 18 to <= 65 years | 57 | 59 | 116 |
| > 65 years | 13 | 11 | 24 |
| Sex: Female, Male(Participants) | Benralizumab 30 mg | Mepolizumab 300 mg | Total |
|---|---|---|---|
| Female | 45 | 39 | 84 |
| Male | 25 | 31 | 56 |
| Ethnicity (NIH/OMB)(Participants) | Benralizumab 30 mg | Mepolizumab 300 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 0 | 4 |
| Not Hispanic or Latino | 61 | 67 | 128 |
| Unknown or Not Reported | 5 | 3 | 8 |
| Race/Ethnicity, Customized(participants) | Benralizumab 30 mg | Mepolizumab 300 mg | Total |
|---|---|---|---|
| White | 53 | 57 | 110 |
| Asian | 9 | 8 | 17 |
| Other | 3 | 2 | 5 |
| Not reported | 5 | 3 | 8 |
| Region of Enrollment(participants) | Benralizumab 30 mg | Mepolizumab 300 mg | Total |
|---|---|---|---|
| North America | 16 | 16 | 32 |
| Japan | 4 | 4 | 8 |
| Rest of World | 50 | 50 | 100 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
Ran from Oct 2019 to primary completion in Aug 2023, 45 months.
Results were first posted in Jan 2025, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab